Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Novartis: OPM under pressure - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 25, 2002

    Novartis: OPM under pressure

    Novartis India has posted a net profit of Rs 318 m for 2QFY03, a rise of 48% over corresponding quarter last year. As against Rs 216 m in the corresponding quarter last year. However, the figures for the year are not comparable as the company demerged its agrochemical business, which resulted in this sharp decline in turnover and profits. The company also decided to exit the lens and lens care business of CibaVision with effect from December 2000 due to unviability of the same. The other income has also increased sharply by 276%, which has further aided bottomline.

    (Rs m) 2QFY02 2QFY03 % change
    Sales 1,233 1,306 5.9%
    Other Income 61 231 275.9%
    Expenditure 925 1,074 16.1%
    Operating Profit (EBDIT) 308 232 -24.5%
    Operating Profit Margin (%) 25.0% 17.8%  
    Interest 4 2 -51.2%
    Depreciation 20 54 171.2%
    Profit before Tax 345 407 18.0%
    Extraordinary Income - -  
    Tax 130 89 -31.3%
    Profit after Tax/(Loss) 216 318 47.7%
    Net profit margin (%) 17.5% 24.4%  
    No. of Shares (eoy) (m) 31.7 31.7  
    Diluted Earnings per share* 27.2 40.2  
    P/E (at current price) 6.3  

    Pharma sales for the period closed at Rs 811 m registering a growth of 19% over the previous period. Growth was impacted by lower sales of the company’s transplant and oncology range of products. In late 2001, the company has carved out the Biochemie segment from the existing pharma business to align the portfolio with that of the parent company. The Biochemie sector primarily focuses on the therapeutic segments of Anti-TB, Anti-DUB (gynaecology) Anti-histamines, Antibiotics, Anti-ulcerants, Anti-diabetes and Cardiovascular. This sector registered sales of Rs 289 m declining by 8% compared to same period previous year. On a like to like basis (pharma and Biochemie division consolidated), the company has grown 10%, underperforming industry growth rates due to absence of new products.

    Consumer Healthcare achieved good growth over last year largely driven by its popular OTC brand Calcium Sandoz. An encouraging growth in animal health care business was primarily driven by intensive marketing efforts in cattle and poultry segments and addition of three new licenced-in products in the cattle segment.

    Novartis has initiated several measures to put growth on the fast track. It has launched a strategy to revitalise its mature product portfolio by introducing product extensions and variants. Innovative marketing focused on product customisation and disease administration would supplement Novartis efforts in this direction. Novartis has also identified the high growth CVS segment as a focus area where it proposes to launch brands from the parent portfolio. Introduction of new products will be the key growth driver for Novartis. Given Novartis AG’s strong pipeline of 69 drugs under development, one can expect a further ramp up in product introductions in future. NIL also plans to enter into co-marketing and alliances besides brand acquisitions to step up the growth momentum.brands and new introductions to drive growth.

    At the current market price of Rs 213 , the stock trades at 6x 2QFY02 earnings. The future growth of the company depends on the success of the new products launched recently.We think the worry at the moment is the uncertainty over a new price control regime that is likely to bring the flagship brands of Novartis − Voveran, Regestrone and Otrivin − under price control. These brands accounted for 28% of retail sales of the company in the past 12 months. We estimate that this would translate into 16% of total sales or Rs760m revenues. In the past, when a new drug was brought under price control, the government has ordered a substantial downward revision in price. Assuming a modest 20% price cut would mean a loss of sales in FY03E of Rs167m and lower profit estimate of Rs602m against Rs753m currently. Such a 20% fall in profits would also affect our valuation of the company.



    Equitymaster requests your view! Post a comment on "Novartis: OPM under pressure". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 17, 2017 (Close)


    • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Detailed Financial Information With Charts